Mittie Doyle, serving as the Chief Medical Officer for Avalo Therapeutics, Inc. (NASDAQ: AVTX), has executed a sale of 1,450 shares of common stock. The transaction, completed on June 23, 2026, resulted in a total value of $26,100. This disposition of shares was facilitated through a pre-arranged Rule 10b5-1 trading plan, which Doyle established on November 13, 2025. The structure of this plan ensures that the sale is conducted according to a predetermined schedule, independent of internal market timing considerations.
Before the sale, Doyle acquired the 1,450 shares by exercising stock options at a price of $8.04 per share, totaling $11,657. These options were part of a grant that vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued service. Following these transactions, Doyle directly holds 51,776 shares of Avalo Therapeutics common stock. Additionally, Doyle holds 116,871 derivative shares in the form of stock options.
The insider activity comes at a time when Avalo Therapeutics shares have surged 279% over the past year. The stock is currently trading at $18, with a market capitalization of $948 million. According to InvestingPro analysis, the stock is trading near its Fair Value, with analysts setting price targets ranging from $34 to $60. This significant price appreciation raises questions about executive positioning and valuation perceptions within the biopharmaceutical sector.
In other recent news, Avalo Therapeutics announced the appointment of Ron Philip to its board of directors. Philip, who brings over 30 years of biopharmaceutical experience, will serve until the 2027 Annual Meeting of Stockholders and join several committees. The company also reported plans to submit an Investigational New Drug application for AVTX-010 in the first half of 2027, targeting hidradenitis suppurativa and other inflammatory disorders. Additionally, Avalo Therapeutics amended terms for its preferred stock, allowing an investor to increase its beneficial ownership limit. This change involves exchanging Series C non-voting convertible preferred stock for newly created Series C-1 shares.
Furthermore, BofA Securities initiated coverage on Avalo Therapeutics with a buy rating, highlighting positive phase 2 data for the drug abdakibart in treating hidradenitis suppurativa. These developments reflect Avalo Therapeutics’ ongoing strategic initiatives and analyst interest in its pipeline. The combination of insider selling, strong stock performance, and upcoming regulatory milestones creates a complex landscape for investors evaluating the company's future prospects.